Ovarian Cancer Advocate Named Citizen Of The Year
Tasha Armour's tireless advocacy for ovarian cancer awareness has earnt her a special Australia Day honour.
Armour was one of six women to share her journey with ovarian cancer in a 10 daily video, and her ongoing advocacy has earnt her national praise.
‘Women Are Needlessly Dying’: Calls For Ovarian Cancer Funding As Leading Advocate Farewelled
Six women have candidly shared their gut-wrenching and inspirational ovarian cancer journeys to ensure their voices are heard after Pink Meets Teal founder, Jill Emberson, was farewelled in Newcastle on Jan 23.
Amour was named the Australian of the Year for Shellharbour, NSW in recognition of her efforts in founding Rare Ovarian Cancer Incorporated (ROC Inc.) in 2018.
The not-for-profit was established after doctors found a 17cm mass on her teenage daughter’s ovary.
“My daughter was diagnosed at 16 years of age with a rare ovarian cancer that had received no research throughout the world,” she explained in her acceptance speech.
Armour has since coordinated events and fundraising efforts through her not-for-profit organisation to raise $50,000 for vital research.
“To date, our team has not only started raising money for that research, but we created the world’s first and largest research for rare ovarian cancer.”
She went on to thank her ROC Inc. team, which is “vast and absolutely amazing”, as they danced in the audience.
“I thank you all for your support and commitment to helping us to achieve so much.”
Amour also thanked the community and local businesses that have worked with ROC Inc.
“Without your support, we would not be able to get here so far in such a short period of time.”
With her daughter watching on in the audience, Armour urged other to learn the ovarian cancer symptoms and help increase awareness.
Let’s get the message out there so that we can help improve the overall survival statistics.
The five-year survival rate for ovarian cancer is just 46 percent and is the the most common cause of gynaecological cancer death.
These statistics haven't changed in 30 years in comparison to cancers that receive dedicated funding and advocacy such as breast cancer, which had a 91 percent five-year survival rate.